FDA Grants Priority Review to Sarclisa for Multiple Myeloma

Sarclisa was granted a priority review by the Food and Drug Administration for patients newly diagnosed with multiple myeloma who are ineligible for blood transplants.

Related Keywords

United States ,American ,Dietmar Berger ,Drug Administration ,American Society Of Clinical Oncology ,National Cancer Institute ,Clinical Oncology ,Annual Meeting ,Study Shows Complete Response ,Patients With Multiple ,